[1]曹志超,贺克武.肝细胞癌TACE术后影像学检查技术新进展[J].介入放射学杂志,2025,34(02):218-222.
　CAO Zhichao,HE Kewu..Recent advance in imaging examination techniques for hepatocellular carcinoma after transcatheter hepatic artery chemoembolization[J].journal interventional radiology,2025,34(02):218-222.
点击复制

肝细胞癌TACE术后影像学检查技术新进展()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
34
期数:
2025年02
页码:
218-222
栏目:
综述
出版日期:
2025-02-17

文章信息/Info

Title:
Recent advance in imaging examination techniques for hepatocellular carcinoma after transcatheter hepatic artery chemoembolization
作者:
曹志超; 贺克武
Author(s):
CAO Zhichao; HE Kewu.
Imaging Center of the Third Affiliated Hospital of Anhui Medical University，Hefei，Anhui Province 230061，China
关键词:
【关键词】肝细胞癌; 经导管肝动脉化疗栓塞术; 锥形束计算机断层扫描; 能谱CT; 磁共振功能成像; 超声造影; 正电子发射计算机断层显像; 影像组学
文献标志码:
A
摘要:
【摘要】肝细胞癌的发病率及恶性程度很高，临床上大多数患者一经发现即为中晚期。经导管肝动脉化疗栓塞术（TACE）是不可切除性肝癌患者的首选治疗方式，能够显著减轻患者的痛苦。目前常使用增强CT或增强MR评估TACE的疗效，但对TACE术后肿瘤反应的早期和客观准确评估尚有一定困难。近年来锥形束计算机断层扫描、能谱CT、磁共振功能成像、超声造影、正电子发射计算机断层显像、影像组学等方法的出现使得更加微观及客观地反映肿瘤变化成为可能。该文就肝细胞癌TACE后影像学检查的新进展进行综述。

参考文献/References:

［1］Wang Y，Deng B.Hepatocellular carcinoma：molecular mechanism，targeted therapy，and biomarkers［J］.Cancer Metastasis Reviews，2023，42：629-652.
［2］Hatanaka T，Yata Y，Naganuma A，et al.Treatment strategy for intermediate-stage hepatocellular carcinoma：transarterial chemoembolization，systemic therapy，and conversion therapy［J］.Cancers （Basel），2023，15：1798.
［3］陈晓明，程永德.中期肝癌TACE之争论与研究现状［J］.介入放射学杂志，2021，30：751-755.
［4］Zhang C，Chen X，Wang J，et al.Diagnostic values of contrast-enhanced MRI and contrast-enhanced CT for evaluating the response of hepatocellular carcinoma after transarterial chemoembolisation：a meta-analysis［J］.BMJ Open，2024，14：e070364.
［5］Schobert I，Chapiro J，Pucar D，et al.Fluorodeoxyglucose PET for monitoring response to embolotherapy （transarterial chemoembolization） in primary and metastatic liver tumors［J］.PET Clin，2019，14：437-445.
［6］Peisen F，Maurer M，Grosse U，et al.Intraprocedural cone-beam CT with parenchymal blood volume assessment for transarterial chemoembolization guidance：impact on the effectiveness of the individual TACE sessions compared to DSA guidance alone［J］.Eur J Radiol，2021，140：109768.
［7］Fronda M，Mistretta F，Calandri M，et al.The role of immediate post-procedural cone-beam computed tomography （CBCT） in predicting the early radiologic response of hepatocellular carcinoma （HCC） nodules to drug-eluting bead transarterial chemoembolization （DEB-TACE）［J］.J Clin Med，2022，11：7089.
［8］Li Z，Jiao D，Si G，et al.Making timely remedial measures after TACE based on the results of cone-beam CT liver perfusion［J］.Int J Hyperthermia，2021，38：428-436.
［9］Li Z，Xu K，Zhou X，et al.TACE sequential MWA guided by cone-beam computed tomography in the treatment of small hepatocellular carcinoma under the hepatic dome［J］.BMC Cancer，2023，23：600.
［10］蒋燕，田玉亭，付志浩.45 keV能谱CT图像与常规CT图像对肝细胞癌TACE术后评估效能的比较［J］.中国中西医结合影像学杂志，2023，21：163-166.
［11］Yue X，Jiang Q，Hu X，et al.Quantitative dual-energy CT for evaluating hepatocellular carcinoma after transarterial chemoembolization［J］.Sci Rep，2021，11：11127.
［12］王军，沈加林.能谱CT在肝癌TACE术后评估中的应用［J］.介入放射学杂志，2016，25：439-442.
［13］Choi WS，Chang W，Lee M，et al.Spectral CT-based iodized oil quantification to predict tumor response following chemoembolization of hepatocellular carcinoma［J］.J Vasc Interv Radiol，2021，32：16-22.
［14］Song Y，Xiang Z，Lu Z，et al.Identification of a brand intratumor microbiome signature for predicting prognosis of hepatocellular carcinoma［J］.J Cancer Res Clin Oncol，2023，149：11319-11332.
［15］Saatchian E，Ehsani S，Sarikhani A，et al.Monitoring of the choline/lipid ratio by 1H-MRS can be helpful for prediction and early detection of tumor response to nano-photo-thermal therapy［J］.Lasers Med Sci，2022，37：335-343.
［16］Ou HY，Cheng YF，Chuang YH，et al.Quantification of functional MR predicts early response in post-doxorubicin drug-eluting beads chemoembolization for hepatocellular carcinoma［J］.Dig Dis Sci，2020，65：2433-2441.
［17］Le Bihan D.What can we see with IVIM MRI?［J］.Neuroimage，2019，187：56-67.
［18］Yue X，Lu Y，Jiang Q，et al.Application of intravoxel incoherent motion in the evaluation of hepatocellular carcinoma after transarterial chemoembolization［J］.Curr Oncol，2022，29：9855-9866.
［19］Reddy BM，Valakkadaa J，Ayappan A.Role of intravoxel incoherent motion （IVIM） imaging in response assessment of hepatocellular carcinoma after transarterial chemoembolization （TACE）：a prospective study［J］.Radiologia （Engl Ed），2024，66：23-31.
［20］Fu J，Ye J，Zhu W，et al.Magnetic resonance diffusion kurtosis imaging in differential diagnosis of benign and malignant renal tumors［J］.Cancer Imaging，2021，21：6.
［21］Zeng S，Ma H，Xie D，et al.Tumor multiregional mean apparent propagator （MAP） features in evaluating Gliomas：a comparative study with diffusion kurtosis imaging （DKI）［J］.J Magn Reson Imaging，2024，60：1532-1546..
［22］Lesbats C，Kelly CL，Czanner G，et al.Diffusion kurtosis imaging for characterizing tumor heterogeneity in an intracranial rat glioblastoma model［J］.NMR Biomed，2020，33：e4386.
［23］Yuan ZG，Wang ZY，Xia MY，et al.Diffusion kurtosis imaging for assessing the therapeutic response of transcatheter arterial chemoembolization in hepatocellular carcinoma［J］.J Cancer，2020，11：2339-2347.
［24］Yang DM，Arai TJ，Campbell JW，et al.Oxygen-sensitive MRI assessment of tumor response to hypoxic gas breathing challenge［J］.NMR Biomed，2019，32：e4101.
［25］O′Connor JPB，Robinson SP，Waterton JC.Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI［J］.Br J Radiol，2019，92：20180642.
［26］Li LP，Milani B，Pruijm M，et al.Renal BOLD MRI in patients with chronic kidney disease：comparison of the semi-automated twelve layer concentric objects （TLCO） and manual ROI methods［J］.MAGMA，2020，33：113-120.
［27］Dogra S，Wang X，Gupta A，et al.Acetazolamide-augmented BOLD MRI to assess whole-brain cerebrovascular reactivity in chronic steno-occlusive disease using principal component analysis［J］.Radiology，2023，307：e221473.
［28］Sleight E，Stringer MS，Mitchell I，et al.Cerebrovascular reactivity measurements using 3T BOLD MRI and a fixed inhaled CO2 gas challenge：repeatability and impact of processing strategy［J］.Front Physiol，2023，14：1070233.
［29］Li B，Xu A，Huang Y，et al.Oxygen-challenge blood oxygen level-dependent magnetic resonance imaging for evaluation of early change of hepatocellular carcinoma to chemoembo-lization：a feasibility study［J］.Acad Radiol，2021，28 Suppl 1：S13-S19.
［30］Dietrich CF，Nolsoe CP，Barr RG，et al.Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound （CEUS） in the liver-update 2020 WFUMB in cooperation with EFSUMB，AFSUMB，AIUM，and FLAUS［J］.Ultrasound Med Biol，2020，46：2579-2604.
［31］Watanabe Y，Ogawa M，Kumagawa M，et al.Utility of contrast-enhanced ultrasound for early therapeutic evaluation of hepatocellular carcinoma after transcatheter arterial chemoembolization［J］.J Ultrasound Med，2020，39：431-440.
［32］Mo A，Lin B，Chen D.Efficacy of sequential TACE on primary hepatocellular carcinoma with microvascular invasion after radical resection：a systematic review and meta-analysis［J］.World J Surg Oncol，2023，21：277.
［33］Faccia M，Garcovich M，Ainora ME，et al.Contrast-enhanced ultrasound for monitoring treatment response in different stages of hepatocellular carcinoma［J］.Cancers （Basel），2022，14：481.
［34］Tsujikawa T，Makino A，Mori T，et al.PET imaging of estrogen receptors for gynecological tumors［J］.Clin Nucl Med，2022，47：e481-e488.
［35］Sharma R，Inglese M，Dubash S，et al.Monitoring response to transarterial chemoembolization in hepatocellular carcinoma using 18 F-Fluorothymidine PET［J］.J Nucl Med，2020，61：1743-1748.
［36］张穹，刘纯，陈明，等.肝细胞癌TACE术后病灶存活或复发18 F-FDGPET/CT和增强CT诊断价值Meta分析［J］.中华肿瘤防治杂志，2021，28：302-309.
［37］Galgano SJ，Calderone CE，Xie C，et al.Applications of PET/MRI in abdominopelvic oncology［J］.Radiographics，2021，41：1750-1765.
［38］Brandenberger D，White LM.Radiomics in musculoskeletal tumors［J］.Semin Musculoskelet Radiol，2024，28：49-61.
［39］Cheng S，Hu G，Jin Z，et al.CT-based radiomics nomogram for prediction of survival after transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma and portal vein tumor thrombus［J］.Eur Radiol，2023，33：8715-8726.
［40］Kuang Y，Li R，Jia P，et al.MRI-based radiomics：nomograms predicting the short-term response after transcatheter arterial chemoembolization （TACE） in hepatocellular carcinoma patients with diameter less than 5 cm［J］.Abdom Radiol （NY），2021，46：3772-3789.

相似文献/References:

[1]王有枝,李彦豪,梅雀林,等.原发性肝癌肝动脉化疗栓塞术后继发溶血性尿毒综合征3例并文献复习[J].介入放射学杂志,2016,(06):543.
　WANG You-zhi,LI Yan-hao,MEI Que-lin,et al.Secondary hemolytic uremic syndrome occurring after transcatheter arterial chemoembolization for primary hepatocellular carcinoma: report of 3 cases with literature review [J].journal interventional radiology,2016,(02):543.
[2]蒋健强,李晓娟,李拥军,等.白蛋白-胆红素评分在预测TACE治疗巨块型肝细胞癌后肝功能衰竭中的应用[J].介入放射学杂志,2023,32(01):55.
　JIANG Jianqiang,LI Xiaojuan,LI Yongjun,et al.The application of albumin-bilirubin score in predicting liver failure after transarterial chemoembolization for massive hepatocellular carcinoma [J].journal interventional radiology,2023,32(02):55.
[3]刘　晟,周平盛,沈　强,等.超声引导下微波消融术治疗特殊部位与非特殊部位单发肝细胞癌的疗效对比[J].介入放射学杂志,2023,32(01):36.
　LIU Sheng,ZHOU Pingsheng,SHEN Qiang,et al.Ultrasound-guided microwave ablation for the treatment of single hepatocellular carcinoma located at specific area and at non-specific area: comparison of clinical efficacy[J].journal interventional radiology,2023,32(02):36.
[4]王　曦,冯　苏,李　红,等.免疫检查点抑制剂联合TACE在肝癌治疗中的研究进展[J].介入放射学杂志,2023,32(01):90.
　WANG Xi,FENG Su,LI Hong,et al.Research progress in immune checkpoint inhibitors combined with TACE for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2023,32(02):90.
[5]吴迪,郑琳.载药微球栓塞治疗在肝癌全程管理中的临床应用进展[J].介入放射学杂志,2024,33(08):921.
　WU Di,ZHENG Lin..Application progress of drug-loaded microspheres embolization therapy in the clinical full-process management of hepatocellular carcinoma[J].journal interventional radiology,2024,33(02):921.
[6]陈荔,吴大广,朱光宇,等.经动脉化疗栓塞联合免疫和靶向药治疗Child-Pugh B级肝细胞癌研究[J].介入放射学杂志,2024,33(09):968.
　CHEN Li,WU Daguang,ZHU Guangyu,et al.Transarterial chemoembolization combined with immune checkpoint inhibitor and molecular targeted therapy for Child-Pugh grade B hepatocellular carcinoma[J].journal interventional radiology,2024,33(02):968.
[7]石佳鹏,汤小星,顾祝新,等.TACE联合瑞戈非尼及PD-1二线序贯治疗中晚期肝细胞癌的临床研究[J].介入放射学杂志,2024,33(09):995.
　SHI Jiapeng,TANG Xiaoxing,GU Zhuxin,et al.TACE combined with regorafenib and PD-1 second-line sequential therapy for advanced hepatocellular carcinoma：a clinical study[J].journal interventional radiology,2024,33(02):995.
[8]张岩基,王汇源,李浩,等.经导管动脉化疗栓塞和肝动脉灌注化疗治疗肝细胞癌现状和进展[J].介入放射学杂志,2024,33(09):1039.
　ZHANG Yanji,WANG Huiyuan,LI Hao,et al.Current status and progress of TACE and HAIC in the treatment of hepatocellular carcinoma[J].journal interventional radiology,2024,33(02):1039.
[9]殷梦杰,付守忠,戴锋,等.肝动脉灌注化疗联合卡瑞利珠单抗及索拉非尼治疗中晚期肝癌的疗效与安全性分析 [J].介入放射学杂志,2024,33(11):1212.
　YIN Mengjie,FU Shouzhong,DAI Feng,et al.Hepatic arterial infusion chemotherapy combined with carrelizumab and sorafenib for the treatment of advanced hepatocellular carcinoma：its clinical efficacy and safety[J].journal interventional radiology,2024,33(02):1212.
[10]杜楠,王英,李文涛.肝癌TACE还是HAIC？[J].介入放射学杂志,2024,33(12):1269.
　DU Nan,WANG Ying,LI Wentao..Treatment of hepatocellular carcinoma：TACE or HAIC？[J].journal interventional radiology,2024,33(02):1269.

备注/Memo

备注/Memo:
（收稿日期：2024-01-29）
（本文编辑：新宇）
更新日期/Last Update: 2025-02-17